IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy
Wang, Lei1,2,4; Fu, Jia-ning2,4; Wang, Jing-yu2,4; Jin, Cun-jing2,4; Ren, Xiao-yuan2,4; Tan, Qiang1,2,4; Li, Jing2,4; Yin, Han-wei3; Xiong, Kun3; Wang, Tian-yu3; Liu, Xin-min1; Zeng, Hui-hui2,4
关键词ethaselen NF-kappa B non-small cell lung cancer radiosensitizer thioredoxin reductase inhibitor
刊名ANTI-CANCER DRUGS
2011-09-01
DOI10.1097/CAD.0b013e32834618bc
22期:8页:732-740
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Pharmacology & Pharmacy
资助者Natural Science Foundation of China ; Natural Science Foundation of China
研究领域[WOS]Oncology ; Pharmacology & Pharmacy
关键词[WOS]IONIZING-RADIATION ; KAPPA-B ; APOPTOSIS ; LINES ; CARBOPLATIN ; THERAPY ; GROWTH ; EXPRESSION ; MECHANISM
英文摘要

It has been proposed that thioredoxin reductase (TR) is a mediator that allows non-small cell lung cancer (NSCLC) to develop resistance to irradiation; however, little is known regarding the detailed mechanisms of action. Thus, ethaselen {1, 2-[bis (1,2-benzisoselenazolone-3 (2H)-ketone)] ethane, BBSKE}, a novel organoselenium TR inhibitor, is currently being investigated in a phase I clinical trial in China. However, its radiosensitizing effect remains unexplored. In this study, we found that the activity of TR increased dramatically in both A549 and H1299 cells after radiation, and moreover, could be inhibited by pretreatment with BBSKE (5 mu mol/l). As a TR inhibitor, BBSKE enhanced the efficacy of radiation therapy both in vivo and in vitro without observable toxicity. BBSKE was found to suppress irradiation-induced NF-kappa B activation dramatically when using A549 cells stably transfected with NF-kappa B luciferase reporter. These results show the critical role of TR in the radioresistance of NSCLC and suggest that BBSKE is a potentially promising agent for the treatment of patients with NSCLC clinically. Anti-Cancer Drugs 22:732-740 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.

语种英语
所属项目编号30472036
资助者Natural Science Foundation of China ; Natural Science Foundation of China
WOS记录号WOS:000293212800004
Citation statistics
Cited Times:16[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62847
Collection北京大学第一临床医学院
作者单位1.Peking Univ, Hosp 1, Beijing 100034, Peoples R China
2.Peking Univ, Coll Life Sci, Beijing 100034, Peoples R China
3.Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing, Peoples R China
4.Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Beijing 100034, Peoples R China
Recommended Citation
GB/T 7714
Wang, Lei,Fu, Jia-ning,Wang, Jing-yu,et al. Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy[J]. ANTI-CANCER DRUGS,2011,22(8):732-740.
APA Wang, Lei.,Fu, Jia-ning.,Wang, Jing-yu.,Jin, Cun-jing.,Ren, Xiao-yuan.,...&Zeng, Hui-hui.(2011).Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy.ANTI-CANCER DRUGS,22(8),732-740.
MLA Wang, Lei,et al."Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy".ANTI-CANCER DRUGS 22.8(2011):732-740.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Wang, Lei]'s Articles
[Fu, Jia-ning]'s Articles
[Wang, Jing-yu]'s Articles
百度学术
百度学术Similar articles in
[Wang, Lei]'s Articles
[Fu, Jia-ning]'s Articles
[Wang, Jing-yu]'s Articles
必应学术
必应学术Similar articles in
[Wang, Lei]'s Articles
[Fu, Jia-ning]'s Articles
[Wang, Jing-yu]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.